Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benufutamab - Genmab

Next Previous
Drug Profile

Benufutamab - Genmab

Alternative Names: GEN1029; HexaBody-DR5/DR5; Hx-DR5-01; Hx-DR5-01/05; Hx-DR5-05; iDD 004

Latest Information Update: 28 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iDD Biotech
  • Developer Genmab; VU University Medical Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Multiple myeloma

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in Netherlands
  • 12 Oct 2021 Genmab terminates phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) in USA, United Kingdom, Spain and France (IV) (NCT03576131) (EudraCT2017-001394-16)
  • 26 Oct 2019 Pharmacodynamics data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top